JP2021024849A - ガン細胞の細胞死誘導剤 - Google Patents
ガン細胞の細胞死誘導剤 Download PDFInfo
- Publication number
- JP2021024849A JP2021024849A JP2019150728A JP2019150728A JP2021024849A JP 2021024849 A JP2021024849 A JP 2021024849A JP 2019150728 A JP2019150728 A JP 2019150728A JP 2019150728 A JP2019150728 A JP 2019150728A JP 2021024849 A JP2021024849 A JP 2021024849A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- peroxidase
- cell death
- cancer
- cancer cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract description 47
- 201000011510 cancer Diseases 0.000 title abstract description 47
- 230000030833 cell death Effects 0.000 title abstract description 41
- 230000001939 inductive effect Effects 0.000 title abstract description 7
- 102000003992 Peroxidases Human genes 0.000 claims abstract description 65
- 108040007629 peroxidase activity proteins Proteins 0.000 claims abstract description 65
- 230000004611 cancer cell death Effects 0.000 claims abstract description 14
- 239000004480 active ingredient Substances 0.000 claims abstract description 9
- 239000000411 inducer Substances 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 8
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 abstract description 129
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 abstract description 27
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 abstract description 27
- 210000002744 extracellular matrix Anatomy 0.000 abstract description 27
- 239000002246 antineoplastic agent Substances 0.000 abstract description 9
- 229940041181 antineoplastic drug Drugs 0.000 abstract description 4
- 239000003795 chemical substances by application Substances 0.000 abstract description 3
- 230000003211 malignant effect Effects 0.000 abstract description 3
- 206010059866 Drug resistance Diseases 0.000 abstract 1
- 239000000284 extract Substances 0.000 description 15
- 108090000672 Annexin A5 Proteins 0.000 description 13
- 102000004121 Annexin A5 Human genes 0.000 description 13
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 13
- 229960002949 fluorouracil Drugs 0.000 description 13
- 235000009811 Momordica charantia Nutrition 0.000 description 10
- 240000008067 Cucumis sativus Species 0.000 description 8
- 244000302512 Momordica charantia Species 0.000 description 8
- 206010060862 Prostate cancer Diseases 0.000 description 8
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 8
- 235000008322 Trichosanthes cucumerina Nutrition 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 8
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 6
- 238000004115 adherent culture Methods 0.000 description 6
- 238000010899 nucleation Methods 0.000 description 6
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- 229920002674 hyaluronan Polymers 0.000 description 5
- 229960003160 hyaluronic acid Drugs 0.000 description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 240000003291 Armoracia rusticana Species 0.000 description 3
- 235000011330 Armoracia rusticana Nutrition 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 231100000405 induce cancer Toxicity 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000001000 micrograph Methods 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000006479 redox reaction Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- RLFWWDJHLFCNIJ-UHFFFAOYSA-N 4-aminoantipyrine Chemical compound CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 description 2
- 235000015844 Citrullus colocynthis Nutrition 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 241001660897 Bothrocara Species 0.000 description 1
- 241001660896 Bothrocara hollandi Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 102000008015 Hemeproteins Human genes 0.000 description 1
- 108010089792 Hemeproteins Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000012054 celltiter-glo Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 125000002081 peroxide group Chemical group 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000031877 prophase Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
本発明は、ガン細胞周囲に存在する細胞外マトリックスにペルオキシダーゼの酸化還元反応を起こさせることで、ガン細胞を細胞死に導くために鋭意研究を行い開発されたガン細胞死誘導剤の提供を行うものである。
MDA−MB−231細胞を5000個/wellで96穴マイクロプレート(平底:接着細胞培養プレート)に播種し、DMEM−15%FBS培養液で培養した。
MDA−MB−231細胞を5000個/wellで96穴マイクロプレート(平底:接着細胞培養プレート)に播種し、DMEM−15%FBS培養液で培養した。細胞播種時に実験区分により、4X−HAmatrixを2.5%〜10%並びにペルオキシダーゼ0.44U/mlを加え3日間培養した。
A549細胞を5000個/wellで96穴マイクロプレート(平底:接着細胞培養プレート)に播種し、EMEM−10%FBS培養液で培養した。細胞播種時に実験区分により、4X−HAmatrix15%並びにペルオキシダーゼの濃度を変化させて3日間培養した。
MDA−MB−231細胞を5000個/wellで96穴マイクロプレート(平底:接着細胞培養プレート)に播種し、DMEM−15%FBS培養液で培養した。細胞播種時に実験区分により、4X−HAmatrix0%、4X−HAmatrix0%にペルオキシダーゼ(0.44U/ml)添加、4X−HAmatrix15%添加、4X−HAmatrix15%にペルオキシダーゼ(0.44U/ml)添加の4区を作成し、さらに5−フルオロウラシル(5−FU)を0〜1000μM/ml加え3日間培養した。
MDA−MB−231細胞を50000個/wellで24穴マイクロプレート(平底:接着細胞培養プレート)に播種し、DMEM−15%FBS培養液で培養した。細胞播種時に実験区分により4X−HAmatrix0%、4X−HAmatrix0%にペルオキシダーゼ(0.44U/ml)を添加、4X−HAmatrix15%添加、4X−HAmatrix15%にペルオキシダーゼ(0.44U/ml)添加の4区を作成し、3日間培養した。
PC−3細胞を用いて実験を行った。PC−3細胞を5000個/wellで96穴マイクロプレート(平底:接着細胞培養プレート)に播種し、Ham’s F12−10%FBS培養液で培養した。細胞播種時に4X−HAmatrix15%添加(6a)、4X−HAmatrix15%にペルオキシダーゼ(0.44U/ml)を添加(6b)し、3日間培養した。
A549細胞又はHT−29細胞(ヒト結腸腺ガン細胞)を用いて実験を行った。各細胞を5000個/wellで96穴マイクロプレート(平底:接着細胞培養プレート)に播種し、A549はEMEM−10%FBS培養液を使用し、4X−HAmatrix10%にゴーヤ抽出液を加えて3日間培養した。HT−29細胞はMcCoy’s 5a−10%FBS培養液を使用し、4X−HAmatrix15%にキュウリ抽出液を加えて3日間培養した。
Claims (3)
- ペルオキシダーゼを有効成分として含有するガン細胞死誘導剤。
- 前記ペルオキシダーゼは溶液に溶解しており、前記ペルオキシダーゼの前記溶液中における酵素活性が0.0044U/ml以上であることを特徴とする請求項1に記載するガン細胞死誘導剤。
- ペルオキシダーゼが植物から抽出された酵素であるペルオキシダーゼを有効成分として含有することを特徴とする請求項1又は請求項2に記載するガン細胞死誘導剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019150728A JP7446739B2 (ja) | 2019-08-01 | 2019-08-01 | ガン細胞の細胞死誘導剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019150728A JP7446739B2 (ja) | 2019-08-01 | 2019-08-01 | ガン細胞の細胞死誘導剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021024849A true JP2021024849A (ja) | 2021-02-22 |
JP7446739B2 JP7446739B2 (ja) | 2024-03-11 |
Family
ID=74663075
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019150728A Active JP7446739B2 (ja) | 2019-08-01 | 2019-08-01 | ガン細胞の細胞死誘導剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP7446739B2 (ja) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009215301A (ja) * | 2009-04-27 | 2009-09-24 | Morinaga Milk Ind Co Ltd | プロテアーゼ阻害剤 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5578648B2 (ja) | 2009-09-17 | 2014-08-27 | 地方独立行政法人鳥取県産業技術センター | スフェロイド形成促進剤 |
-
2019
- 2019-08-01 JP JP2019150728A patent/JP7446739B2/ja active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009215301A (ja) * | 2009-04-27 | 2009-09-24 | Morinaga Milk Ind Co Ltd | プロテアーゼ阻害剤 |
Non-Patent Citations (4)
Title |
---|
CANCER GENE THER. (2000) VOL.7, ISSUE 1, P.1414-1420, JPN6023009251, ISSN: 0005011635 * |
CELL. SIGNAL. (2004) VOL.16, ISSUE 1, P.81-88, JPN6023009250, ISSN: 0005011634 * |
FOOD FUNCT. (2018) VOL.9, ISSUE 3, P.1878-1888, JPN6023009252, ISSN: 0005011636 * |
PHARMAZIE (2010) VOL.65, NO.2, P.122-126, JPN6023009246, ISSN: 0005011633 * |
Also Published As
Publication number | Publication date |
---|---|
JP7446739B2 (ja) | 2024-03-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Boya et al. | Autophagy in stem cells: repair, remodelling and metabolic reprogramming | |
Sahra et al. | The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level | |
JP7383488B2 (ja) | 結節性硬化症複合体の処置におけるカンナビジオールの使用 | |
Soto-Pantoja et al. | Angiotensin-(1-7) inhibits tumor angiogenesis in human lung cancer xenografts with a reduction in vascular endothelial growth factor | |
Li et al. | Leonurine attenuates fibroblast-like synoviocyte-mediated synovial inflammation and joint destruction in rheumatoid arthritis | |
KR102639313B1 (ko) | 미분화 세포가 제거된 분화 유도 세포집단, 이의 용도 및 이의 제조 방법 | |
Porter et al. | Does apoptosis‐inducing factor (AIF) have both life and death functions in cells? | |
Youn et al. | Anticancer properties of pomolic acid-induced AMP-activated protein kinase activation in MCF7 human breast cancer cells | |
Shen et al. | Metformin and AICAR regulate NANOG expression via the JNK pathway in HepG2 cells independently of AMPK | |
KR20080071598A (ko) | 암 치료용 지방산 유사체 | |
Xu et al. | Empagliflozin induces white adipocyte browning and modulates mitochondrial dynamics in KK Cg-Ay/J mice and mouse adipocytes | |
Lee et al. | Regulatory effects of Siegesbeckia glabrescens on non-small cell lung cancer cell proliferation and invasion | |
Young et al. | Phase I and clinical pharmacologic evaluation of lonidamine in patients with advanced cancer | |
Quattrocchi et al. | Genetic lesions disrupting calreticulin 3′-untranslated region in JAK2 mutation-negative polycythemia vera | |
EP2102149B1 (en) | Stilbene derivatives for adp-ribosyl cyclase inhibitors | |
Jandova et al. | Somatic alterations in mitochondrial DNA produce changes in cell growth and metabolism supporting a tumorigenic phenotype | |
Min et al. | Heme oxygenase-1 mediates cytoprotection against nitric oxide-induced cytotoxicity via the cGMP pathway in human pulp cells | |
Ohashi et al. | Organic anion transporters, OAT1 and OAT3, are crucial biopterin transporters involved in bodily distribution of tetrahydrobiopterin and exclusion of its excess | |
JP2021024849A (ja) | ガン細胞の細胞死誘導剤 | |
Xu et al. | Expression of autophagy-related factors LC3A and Beclin 1 and apoptosis-related factors Bcl-2 and BAX in osteoblasts treated with sodium fluoride | |
Soares et al. | The combination of Cl-IB-MECA with paclitaxel: A new anti-metastatic therapeutic strategy for melanoma | |
Megat et al. | Antiallodynic action of phosphodiesterase inhibitors in a mouse model of peripheral nerve injury | |
CN104662028B (zh) | 对具有异常的脂肪生成信号的癌症进行治疗的组合物和方法 | |
US20110166223A1 (en) | Methods of inhibiting fgfr3 signaling | |
CN109833321A (zh) | 一种逆转肝癌细胞对sorafenib耐药性的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220510 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230228 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230314 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230502 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230606 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20230606 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230705 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230905 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20231031 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231225 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240227 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240228 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7446739 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |